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94 Poster Session-I3 or 4 weeks before HSCT and continued until discharge. All mi-
crobes including normal flora were specified and their susceptibility
profiles to antimicrobial agents were examined. The sensitivity for
the surveillance culture was defined as the rate of detecting microbes
identical to pathogens of septicemia from throat or feces at least 1
week before the development of septicemia.
Results: Causative pathogens were gram-positive cocci (GPC)
in 19, gram-positive rods (GPR) in 5, and gram-negative rods
(GNR) in 16 episodes. The sensitivity for surveillance cultures
in detecting causative pathogens of septicemia prior to the devel-
opment of septicemia was 42.5% (17 of 40) in all episodes. The
sensitivity was 73.7% (14 of 19) in the septicemia due to GPC,
which was significantly higher than that due to GNR (18.8%; 3
of 16, p\ 0.01).
Conclusions: We conclude that weekly surveillance culture is
useful in predicting the pathogen causing septicemia, particularly
in septicemia due to GPC, after allogeneic HSCT.258
HEMORRHAGIC CYSTITIS (HC) IN HEMATOPOIETIC STEM CELL TRANS-
PLANT (HSCT) RECIPIENTS USING ABLATIVE FLUDARABINE/BUSULFAN
(FB) CONDITIONING WITH AND WITHOUT TOTAL BODY IRRADIATION
(TBI)
Haq, B.1, Sahovic, E.A.1, Rossetti, J.M.1, Shadduck, R.K.1, Atem, F.2,
Lister, J.1 1Western Pennsylania Cancer Institute, Pittsburgh, PA; 2Uni-
versity of Pittsburgh, Pittsburgh, PA
HC is a recognized complication of HSCT, commonly associ-
ated with the use of cyclophosphamide. Ninety one patients under-
went non-cyclophosphamide, intravenous FB conditioning for
HSCT (autologous [AUTO], n 5 11; matched unrelated donor
[MUD], n 5 42; matched related donor [MRD], n 5 38) at our
institution from February 2005 to September 2008. The condi-
tioning regimen consisted of fludarabine 50 mg/m2 /day (5 days),
busulfan 3.2 mg/kg/day (4 days) with or without TBI (200 cGy x
2). Urine was tested for BK virus using electron microscopy or
polymerase chain reaction in most patients who developed HC.
Twenty seven patients received FB with TBI (AUTO, n 5 4,
MUD, n 5 7, MRD, n 5 16) whereas 64 patients received FB
without TBI (AUTO, n 5 7, MUD, n 5 35, MRD, n 5 22). Me-
dian age was 48.6 years (range: 22–81); male: female ratio was
1.7:1. 17% patients developed HC within one year of transplanta-
tion. 6/27 (22%) of patients who received FB with TBI developed
HC whereas 10/64 (16%) of those that received FB alone devel-
oped HC. All patients who developed HC had an allogeneic trans-
plant (MUD, n 5 8; MRD, n 5 8). The median time to
presentation was 36 days post transplant (range: 14–67). HC cases
were graded as follows: grade 1(n 5 4), grade 2(n 5 9), grade 3(n
5 2), grade 4(n 5 1). BKViruria was detected in 12/16 (75%) of
patients with HC. Acute graft versus host disease grade 2–4 was
seen in 4/16 patients. 1/16 patient required urological intervention
(bilateral ureteral stent placement), the rest were treated conserva-
tively. There was no mortality from HC. Addition of TBI to the
FB regimen did not increase the incidence of HC (p 5 0.29).
HC appears to be associated with allogeneic HSCT. HC was
mild to moderate (grade 1–3) in most patients. The late onset of
HC, in our study, suggests that the causative agent was reactivation
of BKV and not direct toxicity from the conditioning regimen,
which typically causes early onset HC.Patient Characteristics and their Association with HC
Patients (n) HC, n (%) P valueAUTO 11 0
MRD 38 8 (21) 0.29
MUD 42 8 (19)
Patient age, years
#48 34 5 (14) 0.047
$48 57 11 (19)Conditioning Regimen
FB 64 10 (16) 0.29
FB 1TBI 27 6 (22)259
A PILOT STUDY OF PROPHYLACTIC LIPOSOMAL AMPHOTERICIN B (AM-
BISOME) FOLLOWED BY MICAFUNGIN (MYCAMINE) FOR 100 DAYS
TO PREVENT INVASIVE MOLD INFECTIONS FOLLOWING ALLOGENEIC
STEM CELL TRANSPLANTATION IN PEDIATRIC RECIPIENTS
El-Mallawany, N.K.1, Tallamy, B.1, Fearon, N.1, van de Ven, C.1,
Bhatia, M.1, George, D.1, Satwani, P.1, Cairo, M.S.1,2,3 1Columbia Uni-
versity, New York, NY; 2Columbia University, New York, NY; 3
Columbia University, New York, NY
Invasive mold infections (IMI) are a significant cause of infec-
tious mortality post allogeneic stem cell transplant (AlloSCT).
We have previously demonstrated the safety and efficacy of liposo-
mal amphotericin B (AMB) for 100 days post AlloSCT in pediatric
recipients (Roman/Cairo et al PBC, 2008). Although AMB is safe
and effective for prophylaxis against IMI post AlloSCT, its associ-
ated nephrotoxicity results in its discontinuation in .10% of
patients. Micafungin is a broad spectrum antifungal active against
yeasts and molds with a markedly diminished side effect profile.
We initiated a pilot study to determine the efficacy and safety of
sequential AMB and Micafungin for antifungal prophylaxis in
pediatric AlloSCT recipients. Twenty-seven patients were given
AMB (3mg/kg/day) IV from d 0–45 and transitioned to Micafun-
gin (1mg/kg/day) IV at d 45 if \ grade II acute graft-
versus-host-disease (GVHD), until d 100. GVHD prophylaxis
was tacrolimus and mycophenolate mofetil (n 5 21) for all patients
as we have previously described (Osunkwo/Cairo et al BBMT,
2004) except those who received CD-34 selected PBSC (T-de-
pleted) who received tacrolimus only (n 5 6). Median age: 8 years
(1–23). Gender: 9F, 18M. Diagnoses: 5-ALL, 6-AML, 2-NHL,
1-NBL, 1-HLH, 4-SAA, 1-b-Thal, 1-MAS, 4-SCD, 1-FA, 1-ALD.
There were 8 CB donors (7-unrelated, 1-related), 6 UPBSC
donors, 11 RBM donors and 2 URBM donors. Median follow-
up is 203 days. The median switch day to Micafungin was 47.
There were no reported side effects attributable to Micafungin
and no one discontinued Micafungin due to toxicity. The probabil-
ity of developing $ grade II acute GVHD and extensive chronic
GVHD was 22.2% and 6.3%, respectively. The probability of
IMI was zero. There were 2 documented invasive fungal infections
(IFI) with Candida Parapsilosis (7.4%) and no Aspergillus IMI.
One IFI occurred on AMB prior to switching to Micafungin, the
other occurred 51 days after switching to Micafungin. All patients
in this cohort are alive at the time of data analysis. Despite a high
population of 60% unrelated donors with 25% receiving T-de-
pleted sources, these preliminary results suggest successive antifun-
gal prophylaxis with AMB and Micafungin is tolerable and
effective in preventing IMI, especially Aspergillus, during the first
100 days post AlloSCT in pediatric recipients. Larger randomized
studies are needed to compare the sequential combination of
AMB/Micafungin to other standard antifungal prophylaxis
regimens.260
LOW INFECTIOUS COMPLICATION RATES IN HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT) RECIPIENTS: BENEFITS OF AMONTHLY
MONITORING SYSTEM
Kindwall-Keller, T.L.1, Cooper, B.W.1, Laughlin, M.J.1, Gerson, S.L.1,
Barr, P.1, Parker, P.2, Jacobs, M.R.3, Creger, R.J.1, Lazarus, H.M.1
1University Hospitals of Cleveland, Case Medical Center, Cleveland,
OH; 2University Hospitals of Cleveland, Case Medical Center, Cleveland,
OH; 3University Hospitals of Cleveland, Case Medical Center, Cleveland,
OH
Life-threatening infections are a common cause of morbidity
and mortality in HSCT recipients. We developed a prospective,
real-time monitoring system for infection reporting and interven-
tion for our inpatient HSCT unit. All positive blood, urine, spu-
tum, skin, and stool cultures as well as Clostridium difficile toxin
tests are reviewed monthly. We use an antibiotic algorithm specific
to our HSCT patients (pts) and an on-going antibiotic restriction
policy has been in place for .25 years. All infections are reviewed
to assess the antimicrobial susceptibility patterns of causative in-
fectious agents and to ensure strict compliance with the antibiotic
algorithm. We performed 995 consecutive HSCT from 1994–
Poster Session-I 952006, autologous (N 5 661), allogeneic (N 5 254), syngeneic (N
5 3), and umbilical cord blood (N 5 77) HSCT. Peripheral blood
(N 5 849) and bone marrow (N 5 69) stem cells were used as
graft sources. Overall, 624 infections were identified (608 cul-
ture-positive) in 385 HSCT pts median age 46 years (male 5
187, female 5 198). HSCT were performed primarily for AML
(N 5 105) and NHL (N 5 79). Documented infections were in-
cluded if they occurred during an inpatient admission within 1
month (mo) prior to and 1–12 mo after HSCT. Several pts had
received multiple HSCT or donor lymphocyte infusions; each
was counted only if there was a documented infection during the
designated time frame. Median (range) number infections/mo
was 4 (1–12). During 9 separate mos in this 13 yr period, there
were $10 infections/mo. A total of 333 bloodstream infections
were identified.
Bloodstream GI Infections
Infections (N5333) N (%) (N5113) N (%)Candida/other
yeast9 (3%) Candida/other
yeast27 (24%)Coagulase negative
Staphylococcus100 (30%) Clostridium difficile
toxin positive75 (66%)Escherichia coli 27 (8%) Rotavirus antigen
positive6 (5%)Enterobacter cloacae 12 (4%)
Enterococcus faecalis 7 (2%) Genitourinary
Infections (N598)
N (%)Enterococcus faecium
excluding VRE5 (2%) Enterococcus
including VRE24 (24%)Klebsiella oxytoca 6 (2%) Escherichia coli 22 (22%)
Klebsiella pneumoniae 36 (11%) Klebsiella pneumoniae 9 (9%)
MRSA 3 (1%)





excluding MRSA13 (4%) Coagulase negative
Staphylococcus4 (11%)VRE 23 (7%) VRE 5 (14%)After bloodstream infections, nosocomial gastrointestinal (GI)
and genitourinary infections were most common. Infectious
pneumonia was uncommon with only 35 documented infections,
Aspergillus species was responsible for 11% (4/35). Gram positive
blood stream infections predominated, most likely associated
with central venous catheter use. Additionally, C. difficile infections
remained an important cause of morbidity and mortality. Despite
absence of global antibiotic prophylaxis (with the exception of
Pneumocystis pneumonia prophylaxis) and not routinely perform-
ing surveillance screening before/during HSCT, we note a low
infectious complication rate over the last 13 yrs. We attribute
our low overall infection rate and lack of major infectious out-
breaks to our system of monthly self-monitoring by our multi-
disciplinary team.CRA-DATA MANAGEMENT
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IMPLEMENTATION OF CHANGE TO THE NEW PATIENT REFERRAL
PROCESS
Willeford, J.F. Texas Oncology - Charles A. Sammons Cancer Center,
Dallas, TX
Prior to April 2008, the process of scheduling new patient office
visits with the Blood and Marrow Transplant physicians was housed
within the affiliated hospital. They were responsible for taking all
new referral phone calls, entering patient information into both phy-
sician and hospital management systems, and scheduling new patient
appointments. Unfortunately, it became evident that there was
a problem with communication and timely scheduling of patients
as the clinic began receiving complaints from referring physicians.It was also confusing for patients when receiving calls from the hos-
pital to schedule for the clinic. The clinic determined that it was nec-
essary to take over the referral process from the hospital.
Management wanted to ensure that referring physician and patient
needs were being met as well as regain control over a process that
directly affected the image of the clinic. It was redesigned to meet
the clinic’s needs:
0 The insurance verification reps absorbed taking the referral
calls. A log was created to track referrals and call backs with
a goal of returning initial calls within 24 hours.
0 A fax was installed at their desk to facilitate receiving medical
records timely.
0 All patient demographics/insurance information is collected
and entered into the clinic’s management system. The reps
began entering the information into the hospital’s management
system as well to simplify communication to the patient and
to the hospital. This minimized the number of calls to the
patient.
0 After verifying the patient’s insurance, the appointment is
scheduled. Since the process is housed in the clinic, communica-
tion has become easier with the physician coordinators thereby
increasing the ability to adjust the physician’s schedule in an
urgent situation.
0 The referring physician’s office is then informed of the
patient’s appointment assuring that the patient has been sched-
uled timely.
0 A packet is sent to the patient with an appointment re-
minder, maps, and necessary paperwork. Completing this
ahead of time saves the patient time once in the clinic. Since
making this change, the clinic has streamlined the new referral
process making great improvements. Referring physicians’
offices are well informed of their patient’s status in being
scheduled; therefore no complaints have been received since
April. In addition, communication amongst clinic and hospital
staff is much more efficient resulting in better customer service
to new patients.262
ALLOWING GREATER USE OF INSTITUTIONAL PRACTICE MAY DECREASE
COST OF CTN TRIALS
Ramakrishnan, A., Buck, T., Levine, J., James, P. University of Michi-
gan, Ann Arbor, MI
Data management for BMT studies can be a time consuming and
expensive task. Patients with complex diseases and complications
can make safety vigilance and protocol adherence a challenge.
When designing a trial, it is important to clearly delineate between
clinical practices that must be dictated because they are vital to the
integrity of the protocol versus ones that can be performed under
the Clinical Practice Guidelines (CPG) of an institution. Often,
when an institution is developing their own trial, they will routinely
allow CPG whenever possible. Trials that are designed by cooper-
ative groups or industry often have numerous specifications that
contradict CPG resulting in a greater data management burden
likely due to more time spent educating staff about differences,
more intensive screening, and reporting of additional data points.
To quantify the differences in data management (DM) hours we
compared DM time for four CTN trials to four similar University
of Michigan (UM) Investigator Initiated trials. This comparison
was facilitated by the routine use of a time and effort tracker tool
utilized by our center for every clinical research study. The time
tracker records the amount of time spent on various trial related
activities such as screening, data collection and safety reporting
for every trial. CTN trials average 31.4 hours more per patient
for data management than UM trials. Using the average cost for
a UM data manager of $29.10 per hour, the cost differential
exceeded $914 per patient. Aside from restricting the use of
CPG, other factors that may add to trial cost are 1) CTN staff
are remotely located and communication is therefore less efficient,
2) CTN trials require an average of 5.18 hours more to screen each
